Peter I Karachunski

Keyphrases

1. Duchenne muscular Dystrophy 100%
2. Acetylcholine Receptor (AChR) 58%
3. Myasthenia Gravis 43%
4. CD4 Cells 32%
5. Epitope 32%
6. CD4+ 29%
7. Torpedo 28%
8. Phase II Trial 27%
9. T Epitopes 21%
10. Ataluren 18%
11. Spinal muscular Atrophy 17%
12. Nonsense mutation Duchenne muscular Dystrophy 17%
13. 6-minute Walk Distance (6MWD) 16%
14. T Cells 16%
15. Epitope Sequence 16%
16. Open-label Extension 16%
17. Placebo-controlled 16%
18. Placebo 14%
19. Pathogenic Variants 13%
20. Motor Function 12%
21. Disease Progression 12%
22. Prednisone 12%
23. Glucocorticoid Therapy 12%
24. Muscular Dystrophy 12%
25. Hypotonia 12%
26. Muscle Acetylcholine Receptor 12%
27. Nasal Administration 12%
28. Clinical Spectrum 12%
29. Rodents 11%
30. Prednisolone 11%
31. Deflazacort 11%
32. Neuromuscular Disease 11%
33. Forced Vital Capacity 11%
34. Dystrophin 11%
35. Dystrophinopathy 11%
36. Randomized Double-blind 11%
37. Acetylcholine Receptor Antibody 10%
38. B-epitopes 10%
39. TANGO2 10%
40. Domagrozumab 10%
41. Clinical Phenotype 10%
42. Facioscapulohumeral muscular Dystrophy 10%
43. Randomized Phase II Trial 10%
44. Non-ambulatory 10%
45. Nicotinic Acetylcholine Receptor (nAChR) 10%
46. Neuromuscular Medicine 10%
47. Diagnostic Approach 10%
48. Early Onset 10%
49. Immunization 10%
50. Myopathic 9%